

<b>Session:</b> Resistance to novel antibiotics and beta-lactamase inhibitors <b>Location:</b> Arena 1 <b>Date:</b> 15 April <b>Time:</b> 11:00-12:00 CEST		
Merck	ALP1304	Activity of imipenem/relebactam and comparators against clinical MDR and DTR Pseudomonas aeruginosa isolates – SMART United States 2019-2021
Pfizer	ALP1306	In vitro activity of ceftibuten-avibactam against Enterobacterales from urinary tract infections collected in the 2022 ATLAS Surveillance Program: A regional analysis
<b>Session: 3. Bacterial susceptibility &amp; resistance Location:</b> Poster Area <b>Date:</b> 15 April <b>Time:</b> 12:00-13:30 CEST		
<b>Session: 3a. Resistance surveillance &amp; epidemiology: MRSA, VRE &amp; other Gram-positives</b>		
La Jolla	P0044	In vitro surveillance of eravacycline against Gram-positive pathogens, including resistant isolates, collected worldwide during 2021
Pfizer	P0021	In vitro activity of ceftaroline and comparator agents against bacterial pathogens frequently isolated from patients with respiratory tract, skin and soft tissue, and bloodstream infections collected during the ATLAS global surveillance programme in 2017-2021
<b>Session: 3b. Resistance surveillance and epidemiology: Gram-negatives</b>		
Merck	P0054	Activity of ceftolozane/tazobactam and comparators against clinical Gram-negative pathogens and resistant phenotypes: SMART United States 2019-2021
Meiji	P0068	Activity of Aztreonam / Nacubatom Against Worldwide 3,656 Clinical Isolates of Enterobacterales Collected Worldwide During 2021
Pfizer	P0086 <i>TOP RATED</i>	In vitro activity of aztreonam-avibactam and comparator agents against Enterobacterales isolates collected from patients in intensive care units compared to other wards, ATLAS Global Surveillance Program, 2017-2021
GARDP	P0091	Searching for carbapenem-sparing regimens to treat ESBL-producing Enterobacterales (ESBL-PE): in vitro susceptibility evaluation of a current global panel of ESBL-PE to selected antibiotics
Pfizer	P0095	In vitro activity of aztreonam/avibactam and comparator agents against carbapenemase-producing Enterobacterales collected as part of the ATLAS Surveillance Programme, 2017-2021
Allegra (Advanz)	P0097	Influence of genotype on the activity of cefepime/enmetazobactam against beta-lactam resistant Enterobacterales collected from Europe in 2019-2021
Pfizer	P0103	In vitro activities of aztreonam-avibactam and comparator agents against metallo-β-lactamase-producing Enterobacterales collected during the ATLAS Global Surveillance Program, 2017-2021
Merck	P0109	Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical gram-negative pathogens before and during the COVID-19 pandemic: SMART United States 2018-2021
Pfizer	P0122	Longitudinal analysis of the in vitro activity of aztreonam-avibactam and comparator agents against Enterobacterales collected globally for the ATLAS surveillance program, 2017-2021
La Jolla	P0139	In vitro surveillance of eravacycline against Enterobacterales and non-fermentor clinical isolates, including resistant isolates, collected in Europe during 2021
Pfizer	P0149	In vitro activity of aztreonam-avibactam and comparator agents against clinical Enterobacterales isolates collected worldwide stratified by global region, ATLAS Global Surveillance Program, 2017-2021
Pfizer	P0150	In vitro activity of ceftazidime-avibactam and comparators against Enterobacterales isolates harboring OXA-48-like carbapenemases, ATLAS Global Surveillance Program 2017-2021
Pfizer	P0155	In vitro activity of ceftazidime-avibactam (CAZ-AVI) and comparators against Pseudomonas aeruginosa collected worldwide stratified by Global Region, ATLAS Global Surveillance Program, 2017-2021
Pfizer	P0164	In vitro activity of ceftazidime-avibactam and comparators against Enterobacterales stratified by global region collected, ATLAS Global Surveillance Program, 2017-2021
Venatorx	P0167	Antimicrobial activity of cefepime in combination with taniborbactam against resistant clinical isolates of Enterobacterales from 2018-2021 global surveillance
Pfizer	P0172	In vitro activity of ceftibuten-avibactam and comparator agents against multidrug-resistant Enterobacterales collected globally as part of the ATLAS Surveillance Program, 2022
Pfizer	P0174	In vitro activity of ceftazidime-avibactam (CAZ-AVI) and comparators against Pseudomonas aeruginosa collected worldwide stratified by ICU vs non-ICU, ATLAS Global Surveillance Program, 2017-2021
Merck	P0178	Activity of imipenem/relebactam against Gram-negative pathogens from paediatric patients in Asia/Pacific – SMART 2019-2021

Merck	P0192	In vitro activity of imipenem/relebactam against Enterobacterales and Pseudomonas aeruginosa from patients with bloodstream infections in the Asia/Pacific region, SMART 2018-2021
Merck	P0194	Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and P. aeruginosa collected in Greece and Italy: SMART 2017-2021
Merck	P0199	Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical Gram-negative isolates collected in Mexico from patients with lower respiratory tract infections – SMART 2017-2021
Pfizer	P0246	In Vitro Activity of aztreonam-avibactam (ATM-AVI) and comparators against Enterobacterales collected worldwide stratified by infection source: ATLAS Global Surveillance Program, 2017-2021
Pfizer	P0249	In vitro activity of ceftazidime-avibactam and comparator agents against MDR Pseudomonas aeruginosa, ATLAS Global Surveillance Program 2017-2021
Venatorx	P0268	Activity of cefepime/taniborbactam against Enterobacterales and P. aeruginosa collected globally in 2018-2021 stratified by $\beta$ -lactamase carriage
Merck	P0274	The activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and P. aeruginosa collected in central-north Europe (Belgium, Norway, Sweden, Switzerland): SMART 2017-2021
Allegra (Advanz)	P0289	Surveillance of cefepime/enmetazobactam against European isolates of Enterobacterales collected between 2019 and 2021, including cephalosporin-resistant phenotypes
Meiji	P0295	Surveillance of cefepime/nacubatom against worldwide 3,656 clinical isolates of Enterobacterales collected worldwide during 2021
Merck	P0303	Antimicrobial susceptibility of Gram-negative bacilli isolated from paediatric infections in Latin-America in 2018 to 2021: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART)
Pfizer	P0309	In vitro activity of aztreonam/avibactam and comparator agents against multidrug-resistant Enterobacterales collected globally as part of the ATLAS Surveillance Programme, 2017-2021
Merck	04870	Global analysis of the in vitro activity of imipenem/relebactam against KPC-encoding Enterobacterales 2018-2021
<b>Session: 3d. Resistance mechanisms incl. in vitro and in vivo studies, mobile elements (excl. TB)</b>		
Shionogi	P0423	Heteroresistance to cefiderocol in Acinetobacter baumannii is not a cause of the imbalance in mortality observed in CREDIBLE-CR
<b>Session: 6. Fungal infection &amp; disease -- Resistance in fungi: a moving field Location: Arena 1 Date: 15 April Time: 17:15-18:15 CEST</b>		
IHMA	MEM0108	Resistance surveillance of antifungal agents in clinical use: data from the 2021 ARIA surveillance initiative, analysis of resistance in antifungals
<b>Session: 5a. Mechanisms of action, new compounds, preclinical data &amp; basic pharmacology of antibacterial agents (incl. investigational and non-traditional therapeutics) Location: Poster Area Date: 17 April Time: 12:00-13:30 CEST</b>		
Bugworks	P2166	Minimum inhibitory concentration evaluation of BWC0977, a novel bacterial topoisomerase inhibitor, against recent drug resistant clinical isolates
Roche	P2127	Activity of the novel antibiotic RG6006 against Acinetobacter spp. and exploration of the susceptibility testing method
<b>Session: 21. New drugs and vaccines Location: Poster Area Date: 18 April Time: 12:00-13:30 CEST</b>		
Cipla	LB008	In vitro activity of the novel ceftriaxone-sulbactam/EDTA combination against carbapenem-non-susceptible Enterobacterales and non-fermenter isolates collected in India and South Africa from 2016 to 2021

## IHMA supports companies needing:

- Pre-clinical studies for regulatory filings
- Global laboratory services for all phases of clinical trials
- Antimicrobial resistance (AMR) surveillance (bacterial and fungal)
- Molecular characterization and detection of infectious agents
- New therapeutic approaches (bacteriophage, vaccine, etc.)
- *In vitro* diagnostic device studies